Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News ImmunoGen Inc IMGN

ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once... see more

Recent & Breaking News (NDAQ:IMGN)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GRPH, ROVR, IMGN

PR Newswire 1 day ago

FDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer

Business Wire 1 day ago

IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN

Business Wire 1 day ago

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 4 days ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROVR, IMGN

Accesswire 5 days ago

ALERT: Juan Monteverde Encourages the Shareholders of IMGN, FRLN, PATI to Take Action

Accesswire 5 days ago

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating ImmunoGen, Inc. Buyout

Newsfile 6 days ago

INVESTOR ALERT: Weiss Law Investigates ImmunoGen, Inc.

Accesswire 6 days ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROVR, IMGN, CNSL, PFIN

PR Newswire 6 days ago

Shareholder Alert: Ademi LLP investigates whether ImmunoGen, Inc. has obtained a Fair Price in its transaction with AbbVie

PR Newswire 6 days ago

IMGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ImmunoGen, Inc. Is Fair to Shareholders

Business Wire 6 days ago

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

PR Newswire 6 days ago

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference

Business Wire November 2, 2023

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

Business Wire November 2, 2023

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 1, 2023

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Business Wire October 27, 2023

Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board

PR Newswire October 23, 2023

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results

Business Wire October 19, 2023

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 29, 2023

ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer

Business Wire September 28, 2023